Trial · NCT07906561
Serum GDF-15 and LGALS3BP as Prognostic Biomarkers in Sepsis
NCT07906561, Not yet recruiting, Inonu University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Serum GDF-15 and LGALS3BP as Prognostic Biomarkers in Sepsis. Trials, record NCT07906561. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07906561
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Serum GDF-15 and LGALS3BP as Prognostic Biomarkers in Sepsis
- NCT number
- NCT07906561
- Status
- Not yet recruiting
- Enrollment
- 150 participants, estimated
- Lead sponsor
- Inonu University
- Conditions
- Sepsis, Septic Shock
- Interventions
- Serum GDF-15 and LGALS3BP Measurement
- First posted
- 2026-10-30
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Serum GDF-15 Concentration | Within 24 hours of ICU admission and at 72 hours | Serum growth differentiation factor-15 (GDF-15) concentration measured by enzyme-linked immunosorbent assay (ELISA), in pg/mL. |
| Primary | Serum LGALS3BP Concentration | Within 24 hours of ICU admission and at 72 hours | Serum galectin-3-binding protein (LGALS3BP) concentration measured by enzyme-linked immunosorbent assay (ELISA), in µg/mL. |
| Primary | 28-Day All-Cause Mortality | 28 days after ICU admission | Number of participants who died from any cause within 28 days of ICU admission. |
| Primary | Change in SOFA Score | From ICU admission to 72 hours | Change in Sequential Organ Failure Assessment (SOFA) score from ICU admission to 72 hours. The SOFA score ranges from 0 to 24, with higher scores indicating more severe organ dysfunction. |
| Secondary | Change in Serum GDF-15 Concentration | From ICU admission to 72 hours | Change in serum GDF-15 concentration measured by ELISA between ICU admission and 72 hours, in pg/mL. |
| Secondary | Change in Serum LGALS3BP Concentration | From ICU admission to 72 hours | Change in serum LGALS3BP concentration measured by ELISA between ICU admission and 72 hours, in µg/mL. |
| Secondary | Area Under the ROC Curve of the Combined GDF-15 and LGALS3BP Panel for 28-Day Mortality | 28 days after ICU admission | Area under the receiver operating characteristic curve (range 0 to 1) of the combined serum GDF-15 and LGALS3BP panel for predicting 28-day all-cause mortality. |
| Secondary | APACHE II Score | Within 24 hours of ICU admission | Acute Physiology and Chronic Health Evaluation II score at ICU admission. Scores range from 0 to 71, with higher scores indicating greater disease severity. |
| Secondary | Number of Participants Requiring Vasopressor Therapy | From ICU admission to 72 hours | Number of participants requiring vasopressor therapy to maintain mean arterial pressure. |
| Secondary | Duration of Invasive Mechanical Ventilation | From ICU admission to extubation or death, assessed up to 28 days | Duration of invasive mechanical ventilation, in days. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07906561
GET https://conductscience.org/api/trials/v1/NCT07906561/registered